Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Summaries for Patients |21 March 2000

The Efficacy of the Drug Epoprostenol in the Treatment of Pulmonary Hypertension Associated with Scleroderma

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information

  • The summary below is from the full report titled “Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease. A Randomized, Controlled Trial.”. It is in the 21 March 2000 issue of Annals of Internal Medicine (volume 132, pages 425-433). The authors are D.B. Badesch, V.F. Tapson, M.D. McGoon, B.H. Brundage, L.J. Rubin, F.M. Wigley, S. Rich, R.J. Barst, P.S. Barrett, K.M. Kral, M.M. Jöbsis, J.E. Loyd, S. Murali, A. Frost, R. Girgis, R.C. Bourge, D.D. Ralph, C.G. Elliott, N.S. Hill, D. Langleben, R.J. Schilz, V.V. McLaughlin, I.M. Robbins, B.M. Groves, S. Shapiro, T.A. Medsger Jr., S.P. Gaine, E. Horn, J.C. Decker, and K. Knob.


Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • What is the problem and what is known about it so far?
    • Why did the researchers do this particular study?
    • Who was studied?
    • How was the study done?
    • hat did the researchers find?
    • hat were the limitations of the study?
    • hat are the implications of the study?
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link

What is the problem and what is known about it so far?

Pulmonary hypertension (high blood pressure in the arteries that go to the lungs) can produce disabling shortness of breath and often causes death. It can occur on its own (primary pulmonary hypertension) but is usually the result of an underlying lung disease, such as scleroderma (secondary pulmonary hypertension). No proven therapies for pulmonary hypertension are known, but epoprostenol, a drug that can dilate narrowed arteries, has shown promise in the treatment of patients with primary pulmonary hypertension.

Why did the researchers do this particular study?

The researchers wanted to see if epoprostenol would be useful in treating pulmonary hypertension that is secondary to scleroderma.

Who was studied?

One hundred eleven patients from 17 pulmonary hypertension centers in the United States with pulmonary hypertension associated with scleroderma.

How was the study done?

The researchers randomly assigned patients to receive either usual treatment or usual treatment plus epoprostenol. For 12 weeks, a pump delivered small amounts of epoprostenol continuously through a small tube inserted into a vein. The researchers measured the degree to which shortness of breath limited patients' activities by observing how far each patient could walk in 6 minutes, both at the beginning of the study and again after 1, 6, and 12 weeks of treatment.

hat did the researchers find?

The 56 patients who got epoprostenol increased the distance they could walk in 6 minutes from 270 to 316 meters. The 55 patients who received only usual therapy could walk 240 meters at the start of the study but only 192 meters at the end. Four epoprostenol patients and 5 usual therapy patients died during the course of the study. Frequent side effects of epoprostenol were jaw pain, diarrhea, nausea, and loss of appetite. Depression also occurred, but less commonly. In addition, patients who got epoprostenol had important side effects, including infection (4 patients) and bleeding (3 patients), that were related to the intravenous tube.

hat were the limitations of the study?

This study included too few patients to show whether epoprostenol improved survival among patients with scleroderma-associated pulmonary hypertension. Patients might find that the side effects and inconvenience of receiving epoprostenol continuously through an intravenous tube are not worth the improvement in exercise ability. It is also unclear whether the benefit observed in the 12 weeks of this study would continue over a longer period.

hat are the implications of the study?

Intravenous epoprostenol appears to improve exercise ability in patients with pulmonary hypertension due to scleroderma. However, associated side effects and the need for intravenous administration may limit the drug's usefulness.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

Not Available
Citations
Citation

The Efficacy of the Drug Epoprostenol in the Treatment of Pulmonary Hypertension Associated with Scleroderma. Ann Intern Med. 2000;132:425. doi: https://doi.org/10.7326/0003-4819-132-6-200003210-00027

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2020

×
Permissions

Published: Ann Intern Med. 2000;132(6):425.

DOI: 10.7326/0003-4819-132-6-200003210-00027

©
2000 American College of Physicians
0 Citations
Advertisement

See Also
Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease: A Randomized, Controlled Trial
View MoreView Less

Related Articles
Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease: A Randomized, Controlled Trial
Annals of Internal Medicine; 132 (6): 425-434
Epoprostenol (Prostacyclin) and Pulmonary Hypertension
Annals of Internal Medicine; 132 (6): 500-502
Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension
Annals of Internal Medicine; 124 (9): 820-824
Pulmonary Hypertension in the CREST Syndrome Variant of Progressive Systemic Sclerosis (Scleroderma)
Annals of Internal Medicine; 86 (4): 394-399
View MoreView Less

Journal Club
SSRI use in late pregnancy was associated with increased persistent pulmonary hypertension in newborns
Annals of Internal Medicine; 156 (10): JC5-11
View MoreView Less

Related Point of Care
Pulmonary Hypertension
Annals of Internal Medicine; 158 (9): ITC5-1
View MoreView Less

Related Topics
Cardiology
Coronary Risk Factors
Hypertension
Nephrology
Pulmonary Hypertension

Cardiology, Coronary Risk Factors, Hypertension, Nephrology, Pulmonary Hypertension.

PubMed Articles
Echocardiographic evaluation of left ventricular filling pressure in patients with heart failure with preserved ejection fraction: usefulness of inferior vena cava measurements and 2016 EACVI/ASE recommendations.
J Card Fail 2020.
Raynaud's phenomenon.
Best Pract Res Clin Rheumatol 2020.
View More

Results provided by: PubMed

Advertisement
CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2020 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×